In a report of cardiac malformations in rats exposed to trichloroethylene (TCE) in drinking water, [@b9-ehp0112-a0607b] used two (1.5 and 1,100 ppm) of the four treatment concentrations that they reported in a previous study ([@b3-ehp0112-a0607b]). To evaluate consistency of results in this single laboratory across the 10-year interval, we compared cardiac defects reported in 2003 by Johnson et al. with those reported in 1993 by Dawson et al. Data from the two papers are shown in [Table 1](#t1-ehp0112-a0607b){ref-type="table"}.

[@b3-ehp0112-a0607b] did not report the number of litters per group, so that correlation was not possible. Regardless, it would be an astonishing coincidence for two studies to produce exactly the same number of fetuses in each group. Still more astonishing is the identical number of "abnormal hearts." Nothing reported by [@b9-ehp0112-a0607b] gives notice that previously published data are being reported again, but that seems to be the inescapable conclusion. If this is a republication of 1993 data, then there has also been reclassification of "defects" with the passage of time.

Another feature of the article by [@b9-ehp0112-a0607b] that attracted our attention was the uncharacteristically large control group (55 litters). One can surmise that in the earlier study ([@b3-ehp0112-a0607b]), each group would have consisted of approximately 10 females, which is consistent with the size of exposed groups (9--13) reported by Johnson et al. Their control group, however, was unprecedentedly large, both in the context of conventional study design and relative to the other groups in this study. [@b9-ehp0112-a0607b] provided no rationale for designing their study with a concurrent control five times larger than the treatment groups, which leads us to ask whether the control group reported here is, in fact, a composite of controls from multiple, perhaps five, different studies. The immediate impact of this large control group is that the very cardiac "abnormalities" at the 1.5 ppm dose that did not differ significantly from controls in 1993 become statistically significant in 2003.

Conventional developmental and reproductive toxicology assays in mice, rats, and rabbits consistently fail to find adverse effects of TCE on fertility or embryonic development aside from embryo- or fetotoxicity associated with maternal toxicity \[[@b1-ehp0112-a0607b]; [@b4-ehp0112-a0607b]; [@b6-ehp0112-a0607b]; [@b7-ehp0112-a0607b]; [@b11-ehp0112-a0607b]; [@b12-ehp0112-a0607b], [@b13-ehp0112-a0607b]; [@b14-ehp0112-a0607b]\]. Johnson and Dawson, with their collaborators, are alone in reporting that TCE is a "specific" cardiac teratogen ([@b2-ehp0112-a0607b], [@b3-ehp0112-a0607b]; [@b5-ehp0112-a0607b]; [@b8-ehp0112-a0607b]; [@b9-ehp0112-a0607b]; [@b10-ehp0112-a0607b]). We have always considered those findings suspect, and our comparison of data from the studies of [@b3-ehp0112-a0607b] and [@b9-ehp0112-a0607b] serves only to intensify our reservations. Studies from this group have potential for important public health and public policy implications, so it is particularly important for the scientific and regulatory communities to have confidence in the conduct and reporting of those studies.

We are also concerned that S.J. Goldberg, one of the authors of the publications alleging that TCE is a selective cardiac teratogen, has been a plaintiff expert in TCE lawsuits and failed to reveal that fact in his publications.

###### 

Cardiac malformations in rats exposed throughout pregnancy to drinking water containing 1.5 or 1,100 ppm TCE.

                                 TCE dose         TCE dose                               
  ------------------------------ ---------- ----- -------------------------------- ----- -----
  L-Transposition (left chest)   1          0     Abnormal looping                 2     0
  Great vessel defect            1          0     Aortic hypoplasia                1     0
  Pulmonary valve defect         1          0     Pulmonary artery hypoplasia      1     0
  Atrial septal defect           4          7     Atrial septal defect             4     7
  Ventricular septal defects                      Ventricular septal defects             
   Subaortic                     2          1      Perimembranous (subaortic)      3     3
   Muscular                      1          4      Muscular                        1     1
  Endocardial cushion defect     0          1     Atrioventricular septal defect   0     1
  Aortic valve defect            0          2     Aortic valve defect              0     2
  No. with abnormal hearts       9          11                                     9     11
  No. fetuses examined           181        105                                    181   105

^a^Data from [@b2-ehp0112-a0607b] Tables 1 and 3, Groups III and IV.

^b^Data from [@b9-ehp0112-a0607b] Table 2; percentage was converted to number.

[^1]: B.D.H. has had no consulting relationships involving TCE. B.J.K. has provided testimony as a defense expert in TCE litigation pertaining to congenital malformations. R.L.B. has provided testimony as a defense expert in TCE litigation pertaining to congenital malformations of the heart.
